Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase

Cardiovascular Research

Volumn 56, Issue 1, 2002, Pages 33-42

  Wang, You Ping ^a   Sato, Chubun ^a   Mizoguchi, Kazuhiro ^a   Yamashita, Yoichi ^a   Oe, Masahiro ^a   Maeta, Hajime ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Endotoxins; Gene expression; Infarction; Ischemia; Nitric oxide; Preconditioning

Indexed keywords

AMINOGUANIDINE; DEXAMETHASONE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE REPERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; DEXAMETHASONE; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUCOCORTICOIDS; GUANIDINES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIPOPOLYSACCHARIDES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 0036775017     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00506-0     Document Type: Article

References (44)

1. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of cell lethal injury in ischemic myocardium. Circulation. 74:1986;1124-1136.
2. Kuzuya T., Hoshida S., Yamashita N., et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 72:1993;1293-1299.
3. Bolli R., Bhatti Z.A., Tang X.L., et al. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res. 81:1997;42-52.
4. Baxter G.F., Marber M.S., Patel V.C., Yellon D.M. Adenosine receptor involvement in a delayed phase of myocardial protection 24 h after ischemic preconditioning. Circulation. 90:1994;2993-3000.
5. ATP channels. Circ Res. 84:1999;846-851.
6. Zhou X., Zhai X., Ashraf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation. 93:1996;1177-1184.
7. Maulik N., Watanabe M., Engelman D., et al. Myocardial adaptation to ischemia by oxidative stress induced by endotoxin. Am J Physiol. 269:1995;907-916.
8. Meng X., Brown J.M., Ao L., et al. Myocardial gene reprogramming associated with a cardiac cross-resistant state induced by LPS preconditioning. Am J Physiol. 275:1998;C475-C483.
9. Zhao L., Weber P.A., Smith J.R., Comerford M.L., Elliott G.T. Role of inducible nitric oxide synthase in pharmacological 'preconditioning' with monophosphoryl lipid A. J Mol Cell Cardiol. 29:1997;1567-1576.
10. Xi L., Jarrett N.C., Hess M.L., Kukreja R.C. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. Circulation. 99:1999;2157-2163.
11. Xi L., Kukreja R.C. Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction. Toxicology. 155:2000;37-44.
12. Elliott G.T., Comerford M.L., Smith J.R., Zhao L. Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide. Cardiovasc Res. 32:1996;1071-1080.
13. He S.Y., Deng H.W., Li Y.J. Monophosphoryl lipid A-induced delayed preconditioning is mediated by calcitonin gene-related peptide. Eur J Pharmacol. 420:2001;143-149.
14. Qiu Y., Rizvi A., Tang X.L., et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 273:1997;H2931-H2936.
15. Wang Y.P., Xu H., Mizoguchi K., Oe M., Maeta H. Intestinal ischemia induces late preconditioning against myocardial infarction: a role for inducible nitric oxide synthase. Cardiovasc Res. 49:2001;391-398.
16. Okamoto H., Ito O., Roman R.J., Hudetz A.G. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Stroke. 29:1998;1209-1218.
17. Tong H., Chen W., London R.E., Murphy E., Steenbergen C. Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol 3-kinase. J Biol Chem. 275:2000;11981-11986.
18. Kelly R.A., Balligand J.L., Smith T.W. Nitric oxide and cardiac function. Circ Res. 79:1996;363-380.
19. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 105:1992;575-580.
20. Lorsbach R.B., Murphy W.J., Lowenstein C.J., Snyder S.H., Russell S.W. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J Biol Chem. 268:1993;1908-1913.
21. Wildhirt S.M., Suzuki H., Horstman D., et al. Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. Circulation. 96:1997;1616-1623.
22. Titheradge M.A. Nitric oxide in septic shock. Biochim Biophys Acta. 1411:1999;437-455.
23. Connelly L., Palacios-Callender M., Ameixa C., Moncada S., Hobbs A.J. Biphasic regulation of NF-κB activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 166:2001;3873-3881.
24. Liu P., Hock C.E., Nagele R., Wong P.Y. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol. 272:1997;2327-2336.
25. Bateson A.N., Jakiwczyk O.M., Schulz R. Rapid increase in inducible nitric oxide synthase gene expression in the heart during endotoxemia. Eur J Pharmacol. 303:1996;141-144.
26. Knowles R.G., Merrett M., Salter M., Moncada S. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem J. 270:1990;833-836.
27. Xia Y., Dawson V.L., Dawson T.M., Snyder S.H., Zweier J.L. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA. 93:1996;6770-6774.
28. Huk I., Nanobashvili J., Neumayer C., et al. L-Arginine treatment alters the kinetics of nitric oxide and superoxide release and induces ischemia/reperfusion injury in skeletal muscle. Circulation. 96:1997;667-675.
29. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 87:1990;1620-1624.
30. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem. 269:1994;4705-4708.
31. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16:1998;225-260.
32. Thanos D., Maniatis T. NF-κB: a lesson in family values. Cell. 80:1995;529-532.
33. Lander H.M., Sehajpal P., Levine D.M., Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol. 150:1993;1509-1516.
34. Geller D.A., Nussler A.K., Di Silvio M., et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA. 90:1993;522-526.
35. Kunz D., Walker G., Eberhardt W., Pfeilschifter J. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1β-stimulated mesangial cell: Evidence for the involvement of transcriptional and post-transcriptional regulation. Proc Natl Acad Sci USA. 93:1996;255-259.
36. Mukaida N., Morita M., Ishikawa Y., et al. Novel mechanism of glucocorticoid-mediated gene repression: Nuclear factor-κB is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem. 269:1994;13289-13295.
37. Griscavage J.M., Wilk S., Ignarro L.J. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB. Proc Natl Acad Sci USA. 93:1996;3308-3312.
38. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 270:1995;286-290.
39. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., Baldwin A.S. Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol. 15:1995;943-953.
40. Misko T.P., Moore W.M., Kasten T.P., et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol. 233:1993;119-125.
41. Hasan K., Heesen B.J., Corbett J.A., et al. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol. 249:1993;101-106.
42. Imagawa J., Yellon D.M., Baxter G.F. Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning. Br J Pharmacol. 126:1999;701-708.
43. Williams M.W., Taft C.S., Ramnauth S., Zhao Z.Q., Vinten-Johansen J. Endogenous nitric oxide (NO) protects against ischaemia-reperfusion injury in the rabbit. Cardiovasc Res. 30:1995;79-86.
44. Ou P., Wolff S.P. Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol. 46:1993;1139-1144.